Response to nivolumab combining radiotherapy and nimotuzumab in metastatic oral squamous cell carcinoma patient with strong PD-L1 expression: a case report

Immune checkpoint inhibitors (ICIs) have been approved for the treatment of oral squamous cell carcinoma (OSCC). However, not all patients would benefit from ICIs. Thus, in order to improve the response rate, the efficacy and safety of combination immunotherapy is still under evaluation. We report a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Xiao, Chen, Shiqing, Sui, Qianqian, Li, Xiaoguang, Liu, Zhonglong, Zhu, Fengshuo, Ding, Jiping, Yao, Yuan, Jiang, Bin, He, Yue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186663/
https://www.ncbi.nlm.nih.gov/pubmed/32355846
http://dx.doi.org/10.21037/atm.2020.02.96

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7186663/
https://www.ncbi.nlm.nih.gov/pubmed/32355846
http://dx.doi.org/10.21037/atm.2020.02.96

Ejemplares similares